NCT00458705View on ClinicalTrials.gov

Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
DRUG

bortezomib

DRUG

dexamethasone

DRUG

pegylated liposomal doxorubicin hydrochloride

DRUG

thalidomide

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00458705 - Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma | Biotech Hunter | Biotech Hunter